Sunshine Biopharma Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed by Sunshine Biopharma Inc. on February 5, 2026. The company is incorporated in Colorado and its common stock (SBFM) and warrants (SBFMW) trade on The Nasdaq Stock Market LLC. The report addresses a specific corporate governance event occurring on the date of the report.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statements or performance data.
Material Changes
The primary material change reported is the departure of a senior executive. On February 5, 2026, Dr. Abderrazzak Merzouki resigned as Chief Operating Officer of Sunshine Biopharma Inc., effective immediately.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, forward-looking outlook statements, or specific risk factors related to the resignation. No compensatory arrangements or unusual items were disclosed in this report.
Key Facts for Investor Verification
- Dr. Abderrazzak Merzouki has resigned as Chief Operating Officer effective February 5, 2026.
- The resignation was reported as immediate with no stated replacement in this filing.
- The report was signed by Dr. Steve N. Slilaty, Chief Executive Officer.
- No financial performance data is included in this specific 8-K filing.